Paolo Paoletti

SVP - Oncology - Head R&D Unit

GlaxoSmithKline

United States

Professional Summary

Long term Senior Executive experience in Research and Development in the pharmaceutical Company.Considered among the top 10 experts in Drug development and recognized to build successfully working team.Succesfully conducted submissions and approval of new medicines for the treatment of lung and breast cancers as well blood diseases: Pemetrexed (Alimta)Lapatinb (Tykerb)Eltrombopag (Promacta)The innovative modalities to reduce the toxicity of Pemetrexed has been reported in the front page of WSJHe also drove the submission for new indications for Gemcitabine (Gemzar).Recently he lead the team for new additional submissions for two new medicines: Ofatumumab for the treatment of CLL and Pazopanib for the treatment of renal cancer.Dr. Paoletti has a cross-functional managerial experience within the global environmentSolid Academic background as professor at the University of Pisa, in Italy and more than 360 publications

Skills

Specialization

Clinical Research, Discovery and, Medical Research/Drugs